Skip to content
DeepViews

Valneva SE American Depositary Shares (VALN) — Analysis Summary

Valneva SE American Depositary Shares (VALN) has a market cap of $622.04M with year-over-year revenue growth of +7.8%. Net margin stands at -66.0%. The stock trades at a P/E ratio of -4.8.

Key Takeaways

  • Revenue changed +7.8% year-over-year
  • Net margin of -66.0%
  • P/E ratio of -4.8

Compared with its sector, VALN posted revenue growth of +7.8% and trades at a P/E of -4.8.

[XNAS]

Valneva SE American Depositary Shares (VALN)

$6.43

UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR

Market Cap
$622.04M
Enterprise Value
$493.20M
P/E Ratio
-4.8
Div Yield
0.00%
EV/EBITDA
-7.2
Company Profile
About
About Valneva SE American Depositary Shares

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Employees

674

Exchange

XNAS

Website
Source: Polygon.io
Score
Competitive Moat
Competitive Moat
37
No Moat

Systematic competitive advantage assessment based on 4yr data

This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.

Market Signals
Valuation
Earnings
Insider Activity
Insider Filing Activity

First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.

Loading SEC insider filing activity...
Superinvestors
Financial Health
Financial Health

Capital Structure

Total Equity$124.75M
Total Debt$0.00M
Debt-to-Equity0.00
Cash & Equivalents$128.84M

Cash Flow

Operating Cash Flow$-59.84M
Free Cash Flow$-64.84M
FCF Margin-32.81%
P/FCF Ratio-9.59
Source: Polygon.io · SEC EDGAR
Dividends
Recent News
Recent News

Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.